When something goes wrong with an AI assistant, our instinct is to ask it directly: "What happened?" or "Why did you do that?

It offered multiple conflicting reasons for its absence, some of which were controversial enough that NBC reporters wrote ...

Version 2.0 of the study will add bunny scent to the stuffed rabbits if motion and heat aren’t enough to fool the pythons in ...

Clinical-stage biotech Recursion Pharmaceuticals ' (NASDAQ: RXRX) stock took it on the chin in the first trading day of the week. Monday saw investors back out of the company's shares, leaving ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.95, marking a -5.71% move from the previous day.

Investors weren't cheered by news from one of the biotech's rivals. Clinical-stage biotech Recursion Pharmaceuticals ' (RXRX -4.66%) stock took it on the chin in the first trading day of the week.

Before market open on Tuesday, Recursion Pharmaceuticals (RXRX 2.27%) published its latest set of quarterly earnings and business update.

10 stocks we like better than Recursion Pharmaceuticals › Clinical-stage biotech Recursion Pharmaceuticals ' (NASDAQ: RXRX) stock took it on the chin in the first trading day of the week.

Explore insights on Recursion Pharmaceuticals' pipeline as mixed clinical data and upcoming 2025 studies shape its future potential.